A Review of Lineage Cell Therapeutics Inc (AMEX: LCTX)’s Performance and Growth Prospects

In the last trading session, 1.33 million Lineage Cell Therapeutics Inc (AMEX:LCTX) shares changed hands as the company’s beta touched 1.27. With the company’s per share price at $1.08 changed hands at $0.0 or 0.00% during last session, the market valuation stood at $203.56M. LCTX’s last price was a discount, traded about -45.37% off its 52-week high of $1.57. The share price had its 52-week low at $0.84, which suggests the last value was 22.22% up since then. When we look at Lineage Cell Therapeutics Inc’s average trading volume, we note the 10-day average is 1.21 million shares, with the 3-month average coming to 1.74.

Lineage Cell Therapeutics Inc (AMEX:LCTX) trade information

With action 3.85%, the performance over the past five days has been green. The company’s shares are showing year-to-date downside of -0.92%, with the 5-day performance at 3.85% in the green. However, in the 30-day time frame, Lineage Cell Therapeutics Inc (AMEX:LCTX) is -4.42% down. Looking at the short shares, we see there were 8.46 million shares sold at short interest cover period of 10.38 days.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.

Lineage Cell Therapeutics Inc (LCTX) estimates and forecasts

Data shows that the Lineage Cell Therapeutics Inc share is performing relatively much not better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -25.00% over the past 6 months, a 6.67% in annual growth rate that is considerably lower than the industry average of 15.50%. Moreover, analysts have looked to lower expectations by upgrading its fiscal year 2024 revenue estimates. The rating firms predict current quarter revenue for Lineage Cell Therapeutics Inc will fall -33.30%, while the growth in revenue is estimated to hit -33.30% for the next quarter. Year-over-year growth is forecast to reach -36.40% down from the last financial year.

Consensus estimates given by 6 financial analysts project the company’s revenue in the current quarter to hit an average of $1.13 million. 3 analysts are of the opinion that Lineage Cell Therapeutics Inc’s revenue for the quarter ending Mar 2024 will be $690k. The company’s revenue for the corresponding quarters a year ago was $1.92 million and $2.01 million respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at -41.00%. The estimates for the next quarter sales put growth at -65.70%.

Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 1.87%. The 2024 estimates are for Lineage Cell Therapeutics Inc earnings to increase by 9.52%.

LCTX Dividends

Lineage Cell Therapeutics Inc is expected to release its next quarterly earnings report between March 07 and March 11.

Lineage Cell Therapeutics Inc (AMEX:LCTX)’s Major holders

If we look at who the major shareholders are, we find that insiders hold 4.11% of Lineage Cell Therapeutics Inc shares while 43.71% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 45.59%. There are 43.71% institutions holding the Lineage Cell Therapeutics Inc stock share, with Broadwood Capital, Inc. the top institutional holder. As of Jun 29, 2023, the company held 19.96% of the shares, roughly 34.94 million LCTX shares worth $49.26 million.

Blackrock Inc. holds the second largest percentage of outstanding shares, with 5.15% or 9.01 million shares worth $12.71 million as of Jun 29, 2023.

Among Mutual Funds, the top two as of Jun 29, 2023 were Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF. With 4.52 million shares estimated at $6.38 million under it, the former controlled 2.59% of total outstanding shares. On the other hand, iShares Russell 2000 ETF held about 1.45% of the shares, roughly 2.54 million shares worth around $3.35 million.

On Key

Related Posts